Intas Pharmaceuticals Ltd. resumed manufacturing cisplatin, a common generic cancer drug that’s been rationed by doctors across the US due to shortages.
Prior to the shortages, which began this year after quality issues emerged at the Indian drugmaker, Intas made about half the US cisplatin supply.
The US Food and Drug Administration noted the resumption of manufacturing of the drug, which is marketed by Intas US unit Accord Healthcare, on its website Monday.
An FDA spokesperson confirmed the resumption of cisplatin manufacturing at Intas. Accord didn’t immediately respond to a request for comment.
